1. Home
  2. CGEN vs BGX Comparison

CGEN vs BGX Comparison

Compare CGEN & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • BGX
  • Stock Information
  • Founded
  • CGEN 1993
  • BGX 2010
  • Country
  • CGEN Israel
  • BGX United States
  • Employees
  • CGEN N/A
  • BGX N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • BGX Trusts Except Educational Religious and Charitable
  • Sector
  • CGEN Health Care
  • BGX Finance
  • Exchange
  • CGEN Nasdaq
  • BGX Nasdaq
  • Market Cap
  • CGEN 142.8M
  • BGX 163.6M
  • IPO Year
  • CGEN 2000
  • BGX N/A
  • Fundamental
  • Price
  • CGEN $1.60
  • BGX $12.87
  • Analyst Decision
  • CGEN Strong Buy
  • BGX
  • Analyst Count
  • CGEN 2
  • BGX 0
  • Target Price
  • CGEN $4.00
  • BGX N/A
  • AVG Volume (30 Days)
  • CGEN 445.1K
  • BGX 67.9K
  • Earning Date
  • CGEN 11-12-2024
  • BGX 01-01-0001
  • Dividend Yield
  • CGEN N/A
  • BGX 10.34%
  • EPS Growth
  • CGEN N/A
  • BGX N/A
  • EPS
  • CGEN 0.02
  • BGX N/A
  • Revenue
  • CGEN $59,852,000.00
  • BGX N/A
  • Revenue This Year
  • CGEN $57.27
  • BGX N/A
  • Revenue Next Year
  • CGEN N/A
  • BGX N/A
  • P/E Ratio
  • CGEN $88.75
  • BGX N/A
  • Revenue Growth
  • CGEN 698.03
  • BGX N/A
  • 52 Week Low
  • CGEN $1.35
  • BGX $10.69
  • 52 Week High
  • CGEN $3.03
  • BGX $12.44
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 51.01
  • BGX 48.49
  • Support Level
  • CGEN $1.55
  • BGX $12.99
  • Resistance Level
  • CGEN $1.68
  • BGX $13.21
  • Average True Range (ATR)
  • CGEN 0.08
  • BGX 0.13
  • MACD
  • CGEN 0.01
  • BGX -0.01
  • Stochastic Oscillator
  • CGEN 52.17
  • BGX 31.11

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

Share on Social Networks: